Toll-like Receptor (TLR) Agonist

TLR7 agonist 3 (compound 2) is a TLR7 agonist and can be used for the stuy of cancers.

FITC-labeled ODN 2395 (sodium), a C class oligodeoxynucleotide, is a TLR9 agonist. FITC-labeled ODN 2395 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

PF-4878691 (3M-852A) is an orally active TLR7 agonist. PF-4878691 has the innate immune response activity, antiviral efficacy against HCV, and can be used for the research of cancer.

Resiquimod-d₅ is deuterium labeled Resiquimod. Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.

FSL-1, a bacterial-derived toll-like receptor 2/6 (TLR2/6) agonist, enhances resistance to experimental HSV-2 infection.

FITC-labeled ODN 1018 (sodium),an oligodeoxynucleotide, is a TLR-9 agonist. FITC-labeled ODN 1018 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

TLR7/8 agonist 4 (compound 41) is a potent TLR7/8 agonist. TLR7/8 agonist 4 has anti-cancer activity.

AXC-715 (T785) trihydrochloride is a TLR7/TLR8 dual agonist. AXC-715 trihydrochloride can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants.

3D-Monophosphoryl Lipid A-5 (3D-MPLA-5) is a TLR agonist that serves as a vaccine adjuvant and enhances the immunogenicity of vaccines.

FAM-labeled ODN 1826 sodium, a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. FAM-labeled ODN 1826 sodium can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy or flow cytometry.

LHC-165 is a TLR7 agonist. LHC-165 has potential to used in study of solid tumors.

AXC-715 (T785) hydrochloride is a TLR7/TLR8 dual agonist. AXC-715 can be used for synthesis of antibody-adjuvant immunoconjugates, comprising an antibody construct that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants.

Bropirimine (U-54461; U-54461S; PNU-54461) is an orally active TLR7 agonist. Bropirimine inhibits RANKL-induced osteoclast differentiation of mouse bone marrow-derived macrophages (BMMs). Bropirimine exhibits dose-dependent direct inhibitory effects on colony formation of cultured KK-47 and 724 cells. Bropirimine can be used for the study of cancers and bone metabolic disorders such as osteoporosis.

SM-324405 is a TLR7 agonistic antedrug (EC₅₀ = 50 nM), with pEC₅₀ values of 7.3 and 6.6 for human TLR7 and Rat TLR7, respectively. SM-324405 is used for immunoresearch of allergic diseases. An antedrug is defined as a locally active compound that is designed to be rapidly metabolized to an inactive form upon entry into the circulation and prevents systemic toxicity by losing its agonistic activity in a plasmatic environment.

TLR8 agonist 5 is a potent TLR8 agonist with an EC₅₀ value of 20 nM for HEK-Blue hTLR8. TLR8 agonist 5 activates the immune response.

FITC-labeled ODN 2216 (sodium) is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. FITC-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

TLR7/8 agonist 6 is a TLR7/8 agonist with EC₅₀s of 0.18 μM and 5.34 μM in TLR7 or TLR8 HEK-SEAP reporter cells, respectively. TLR7/8 agonist 6 potently stimulates production of TNFα, IFNγ, and IL-1β. TLR7/8 agonist 6 can be used for research on cancer and infectious diseases.

MTvkPABC-P5d TFA, a TLR7 agonist, is an immune stimulant. MTvkPABC-P5d TFA can be used for synthesis of immune-stimulating antibody conjugates (ISACs).

TLR7 agonist 2 is a potent and selective Toll-like Receptor 7 (TLR7) agonist with a LEC of 0.4 μM.

BNT411 is a selective TLR7 agonist that can induce the release of IFNa both in vivo and in vitro. BNT411 has anticancer activity and can be used in cancer research, including non-small cell lung cancer, pancreatic cancer, and untreated extensive-stage small cell lung cancer (ES-SCLC).